What is HC Wainwright’s Estimate for TBPH FY2028 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at HC Wainwright issued their FY2028 EPS estimates for Theravance Biopharma in a research note issued to investors on Tuesday, February 25th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of $1.11 per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s FY2029 earnings at $3.87 EPS.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%.

Theravance Biopharma Stock Up 1.2 %

TBPH stock opened at $9.08 on Wednesday. The company has a market capitalization of $446.50 million, a P/E ratio of -8.99 and a beta of 0.21. The company has a 50-day simple moving average of $9.35 and a 200 day simple moving average of $8.91. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Newtyn Management LLC lifted its holdings in Theravance Biopharma by 5.7% in the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock valued at $44,767,000 after acquiring an additional 258,337 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Theravance Biopharma by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company’s stock valued at $8,121,000 after acquiring an additional 4,823 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in Theravance Biopharma by 9.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company’s stock valued at $7,847,000 after acquiring an additional 69,178 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company’s stock valued at $5,211,000 after acquiring an additional 95,304 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Theravance Biopharma by 10.9% in the 4th quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company’s stock valued at $4,665,000 after acquiring an additional 48,635 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.